SIGLEC10 and neuroblastoma: These may therefore be used as possible modulatory targets for NB treatment: semaphorin 6D (SEMA6D)/triggering receptor expressed on myeloid cells 2 (TREM2), galectin-9 (LGALS9)/hepatitis A virus cellular receptor 2 (HAVCR2), and cluster of differentiation 24 (CD24)/sialic acid binding Ig-like lectin 10 (SIGLEC10) (Figure 5C).